Increasing evidence demonstrates the neuroprotective effects of PPAR-γ agonists in a variety of preclinical models of neurological disorders such as Alzheimer's disease [24–26], Parkinson's disease [27], amyotrophic lateral sclerosis [28], Huntington's disease [29], and ischemic damage [30]. This evidence concerns the gene PPARG and juvenile Huntington disease.